Related Experiment Videos
Lymphoseek: a molecular radiopharmaceutical for sentinel node detection.
Anne M Wallace1, Carl K Hoh, David R Vera
1Department of Surgery, University of California, San Diego Comprehensive Cancer Center, USA. amwallace@ucsd.edu
Annals of Surgical Oncology
|June 10, 2003
Summary
Lymphoseek, a novel radiopharmaceutical, showed faster clearance from injection sites and similar sentinel node uptake compared to filtered [(99m)Tc]sulfur colloid (fTcSC) in breast cancer patients.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Nuclear Medicine
Background:
- Lymphoseek is a novel radiopharmaceutical targeting macrophage receptors in lymphatic tissue.
- Sentinel lymph node biopsy is crucial for breast cancer staging.
Purpose of the Study:
- To compare the safety and efficacy of Lymphoseek versus filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in breast cancer patients.
Main Methods:
- A Phase I clinical trial involving 12 breast cancer patients.
- Randomized administration of Lymphoseek or fTcSC with serial imaging over 180 minutes.
- Assay of excised sentinel nodes for radiopharmaceutical uptake.
Main Results:
- Lymphoseek demonstrated significantly faster injection site clearance (2.72 hours vs. 49.5 hours for fTcSC).
- Primary sentinel node uptake was comparable between Lymphoseek and fTcSC (P =.75).
- Lymphoseek showed a lower mean number of detected nodes per study.
Conclusions:
- Lymphoseek offers faster clearance and equivalent sentinel node uptake compared to fTcSC.
- This suggests potential advantages for Lymphoseek in sentinel node detection procedures.